Understanding how platinum chemotherapy affects the immune system in small cell lung cancer
Official title: Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
Funded at University of Texas Hlth Science Center · NIH-11115843 · Data updated 2026-11-12
This research explores why current immune therapies for small cell lung cancer might not work as well as hoped, focusing on how chemotherapy affects the body's immune cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $351,245 |
| NIH project number | 5R01CA269782-04 |
| Project ID | NIH-11115843 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer who are undergoing or have undergone platinum-based chemotherapy and immune checkpoint inhibitor therapy are the focus of this research.
✕Less likely to help
Patients with other types of cancer or those not receiving platinum-based chemotherapy for small cell lung cancer may not directly benefit from this specific line of inquiry.
What this research studies
Small cell lung cancer is a very aggressive type of lung cancer, and while new immune therapies are promising, their effectiveness in this specific cancer has been limited. We believe that the way chemotherapy interacts with the tumor's surroundings and the immune cells within it might be a key factor. This project looks closely at how platinum-based chemotherapy changes the immune cells, called dendritic cells, and their ability to fight the cancer. By understanding these changes, we hope to find new ways to make immune therapies more effective for patients.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to improve the effectiveness of immune therapies for small cell lung cancer patients.
How similar studies have gone: While immune checkpoint inhibitors have shown success in other cancers, their efficacy in small cell lung cancer, especially in combination with platinum chemotherapy, is still being actively explored, making this a novel area of investigation.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Jin, Lingtao — University of Texas Hlth Science Center
- Study coordinator: Jin, Lingtao
Related research
Other NIH-funded projects on the same topics.
-
Role of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC in the Immunotherapy Era
This project looks at whether giving twice-daily radiotherapy for limited-stage small cell lung cancer still helps patients today who are also getting immunotherapy.
-
SCLC model creation and therapy testing
A cancer research program using mouse models and engineered human and mouse cells to study small cell lung cancer and test potential treatments.
-
Impact of genetic changes on SCLC subtypes and treatment response
This project explores how specific genetic changes in small cell lung cancer (SCLC) affect the disease and how it responds to targeted drugs.
-
Repair mechanisms for DNA lesions in small cell lung cancer
Researchers are studying how cancer cells with small cell lung cancer respond or become resistant to treatment by looking at the ways DNA damage is repaired.
-
Understanding how replication stress affects a hard-to-treat breast cancer gene patients may carry
This grant explores how certain breast cancer gene defects interact with replication stress to influence cancer cell survival and treatment resistance, with potential implications for therapies in patients with BRCA2-related breast cancer.
-
Replication Stress Sensing Defects in Small Cell Lung Cancer
A study in people might not be involved directly, but it aims to understand why a common lung cancer responds poorly to therapy over time by examining how cancer cells handle replication stress.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.